Metraipolis › archive › dc_749376cff57e

Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles — Europe PMC PMID:41204962

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41204962
DOI
10.1007/s00467-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-08T17:23:17.665Z
SHA-256 of the archived text
14625c58f425938295f9da675b541b7cc7fe3b6f6b640750aa4d173a5a2dc67b
Stable URL of this page
https://metraipolis.com/documento/dc_749376cff57e

How to cite

Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles — Europe PMC PMID:41204962 — Europe PMC (en), https://europepmc.org/article/MED/41204962 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_749376cff57e (Metraipolis archive dc_749376cff57e, sha256 14625c58f425938295f9da675b541b7cc7fe3b6f6b640750aa4d173a5a2dc67b)
BibTeX
@misc{dc749376cff57e,
  title = {Rituximab in pediatric refractory nephrotic syndrome: a systematic review and meta-analysis evaluating therapeutic efficacy and adverse event profiles — Europe PMC PMID:41204962},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41204962},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_749376cff57e; sha256 14625c58f425938295f9da675b541b7cc7fe3b6f6b640750aa4d173a5a2dc67b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41204962. Agents can read the archived copy with the MCP tool read_document.